Taken together, although it failed to retard tumor growth, ibrutinib monotherapy strikingly inhibited B cell infiltration and function and led to an increase in IRs highly expressing CD8+ T cells in the mouse PCa microenvironment. The gene discussed is CD8A; the disease is neoplasm.